Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inactivated Poliovirus Vaccine (SP059) in Infants in Japan
2015-005187-42Phase 3
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of trivalent inactivated polio vaccine in poliomyelitis, sponsored by Sanofi. Primary endpoints: Primary immunogenicity endpoint and Seroprotection rates against poliovirus types 1, 2, 3.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on 2015-005187-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005187-42.